Resolution of Hidradenitis Suppurativa-Associated Peripheral Ulcerative Keratitis with High-Dose, High-Frequency Infliximab

Main Article Content

Jon Suzich
Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Nidhi Kuchimanchi
Department of Dermatology, University of Virginia, Charlottesville, VA, USA
https://orcid.org/0009-0004-1274-1399
Tara L. McGehee
Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, USA

R. Hal Flowers
Department of Dermatology, University of Virginia, Charlottesville, VA, USA
https://orcid.org/0000-0003-4618-9630
Abby Wills
Department of Dermatology, University of Virginia, Charlottesville, VA, USA

Keywords

hidradenitis suppurativa, inflammatory eye disease, peripheral ulcerative keratitis, tumor necrosis factor (TNF)-alpha inhibitors, infliximab, adalimumab

Abstract

Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by painful nodules, abscesses, and tunnels in intertriginous areas. HS is rarely associated with inflammatory eye disease that can progress to corneal thinning and ulceration. Here, we describe a case of HS-associated peripheral ulcerative keratitis (PUK) treated with infliximab, an intravenous tumor necrosis factor (TNF)-alpha inhibitor, resulting in resolution. Our case demonstrates that high-dose, high-frequency infliximab may have therapeutic potential for severe inflammatory eye disease associated with HS. 

References

1. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. doi:10.1016/j.jaad.2019.08.090.

2. Lee DJ, Desai S, Laurent E, Kopplin LJ. Characterization and management of inflammatory eye disease in patients with hidradenitis suppurativa. Ocul Immunol Inflamm. 2021;29(7-8):1318-1323. doi:10.1080/09273948.2020.1739718.

3. Saygın D, Syed AU, Lowder CY, Srivastava S, Maya JJ, Hajj-Ali RA. Characteristics of inflammatory eye disease associated with hidradenitis suppurativa. Eur J Rheumatol. 2018;5(3):165-168. doi:10.5152/eurjrheum.2018.17163.

4. Dallalzadeh LO, Ang MJ, Beazer AP, Spencer DB, Afshari NA. Peripheral ulcerative keratitis secondary to severe hidradenitis suppurativa. Am J Ophthalmol Case Rep. 2022;25:101403. Published 2022 Feb 5. doi:10.1016/j.ajoc.2022.101403.

5. Alzaga Fernandez AG, Demirci H, Darnley-Fisch DA, Steen DW. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Cornea. 2010;29(10):1189-1191. doi:10.1097/ICO.0b013e3181d4fd5c.

6. Meskin SW, Carlson EM. Mooren's-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review. Ocul Immunol Inflamm. 2011;19(5):340-342. doi:10.3109/09273948.2011.584653.

7. Gargallo-Benedicto A, Clemente-Tomás R, Pastor-Espuig M, et al. Bilateral phlyctenular keratoconjunctivitis in the context of hidradenitis suppurativa: a case report and literature review. Ocul Immunol Inflamm. 2022;30(4):992-994. doi:10.1080/09273948.2020.1833223

8. Abid N, Opran A, Rosner F. Hidradenitis suppurativa complicated by erosive arthropathy and ulcerative keratitis. J Clin Rheumatol. 1999;5(1):29-31. doi:10.1097/00124743-199902000-00006.

9. Gau SY, Liu PY, Chen SN, et al. Risk of keratitis and keratopathy in hidradenitis suppurativa patients: a global federated health network analysis. In Vivo. 2024;38(3):1375-1383. doi:10.21873/invivo.13578.

10. Hassanpour K, H ElSheikh R, Arabi A, et al. Peripheral ulcerative keratitis: a review. J Ophthalmic Vis Res. 2022;17(2):252-275. Published 2022 Apr 29. doi:10.18502/jovr.v17i2.10797.

11. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. doi:10.1056/NEJMoa1504370.

12. van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012;23(4):284-289. doi:10.3109/09546634.2011.571657.

Article Sidebar

PDF
Published
2026-05-11
DOI: https://doi.org/10.25251/mdgz6x13

Article Details

How to Cite
1.
Resolution of Hidradenitis Suppurativa-Associated Peripheral Ulcerative Keratitis with High-Dose, High-Frequency Infliximab. J of Skin. 2026;10(3):3128-3132. doi:10.25251/mdgz6x13
Issue
Vol. 10 No. 3 (2026): May 2026 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.